CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more
CanSino Biologics Inc (CASBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.006x
Based on the latest financial reports, CanSino Biologics Inc (CASBF) has a cash flow conversion efficiency ratio of 0.006x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.90 Million) by net assets ($4.93 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CanSino Biologics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how CanSino Biologics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CanSino Biologics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CanSino Biologics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ARGAN EO 2
F:871
|
N/A |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
0.052x |
|
SIA ENGINEERING CO.
F:O3H
|
N/A |
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
0.104x |
|
R R Kabel Limited
NSE:RRKABEL
|
-0.019x |
|
CANWEL BLDG MATL
F:2CW
|
0.247x |
|
HANOF
PINK:HANOF
|
N/A |
|
Lander Sports Development Co Ltd
SHE:000558
|
-0.135x |
Annual Cash Flow Conversion Efficiency for CanSino Biologics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of CanSino Biologics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.91 Billion | $-168.79 Million | -0.034x | +79.99% |
| 2023-12-31 | $5.29 Billion | $-908.23 Million | -0.172x | +34.07% |
| 2022-12-31 | $7.25 Billion | $-1.89 Billion | -0.261x | -210.54% |
| 2021-12-31 | $8.55 Billion | $2.01 Billion | 0.236x | +404.82% |
| 2020-12-31 | $6.07 Billion | $-469.39 Million | -0.077x | +33.19% |
| 2019-12-31 | $1.47 Billion | $-170.19 Million | -0.116x | +52.98% |
| 2018-12-31 | $502.32 Million | $-123.64 Million | -0.246x | -165.51% |
| 2017-12-31 | $607.33 Million | $-56.30 Million | -0.093x | +42.17% |
| 2016-12-31 | $214.47 Million | $-34.38 Million | -0.160x | -- |